{"id":35696,"topic":"peptides","source":"东方财富","title":"宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道 - 东方财富","url":"https://wap.eastmoney.com/a/202607133802724621.html","url_hash":"86739c1efdc2de3eadec9af9c648fcd064510e74","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5jRjN3SjM0TkZYOFVsTENZUW40eHRCR0RubGJkNmhxV0hIWWh5VWxXTVpRcnN2WjZxbVRnci1qVGVNRmE4TTY4eUtGNFlWYzJLNWVzR2t4dy1iMWhiUzBKSQ?oc=5\" target=\"_blank\">宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">东方财富</font>","content":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在中国化妆品多肽原料行业，维琪科技以6.6%份额位列行业第一。\n客户方面，维琪科技已进入宝洁联合利华、资生堂等国际品牌商及科丝美诗集团、莹特丽集团、韩国科玛集团等国际化妆品制造商的供应商体系，并与丸美、凌博士、迪仕艾普、丝域养发、植物医生、樊文花、欧诗漫、野兽代码、溪木源、HBN、珀莱雅宝洁供应咖啡酰六肽-9原料产品，根据弗若斯特沙利文的研究报告，公司是国内首家向知名国际品牌销售创新新原料的化妆品原料供应商。\n值得注意的是，维琪科技提醒投资者，公司存在毛利率下滑的风险。若未来出现原材料价格及劳动力成本持续上涨、市场竞争加剧、ODM成品业务比例上升、下游客户需求减少等情形，而公司未能采取有效手段控制成本或产品议价能力下降，公司将面临产品成本上升或销售价格下降，高毛利率无法继续维持，进而导致经营业绩下滑的风险。\n（文章来源：21世纪经济报道）","image_url":"https://g1.dfcfw.com/g4/202112/20211206191716.png","lang":"zh","published_at":"2026-07-13T10:24:25+00:00","fetched_at":"2026-07-13T19:15:11+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在…","cluster_id":1656347,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://wap.eastmoney.com/a/202607133802724621.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 593 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":593,"summary_length":221,"usable_text_length":593,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":593,"summary_length":221}},"news_item":{"id":35696,"canonical_url":"https://wap.eastmoney.com/a/202607133802724621.html","source_url":"https://wap.eastmoney.com/a/202607133802724621.html","title":"宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道 - 东方财富","source_name":"东方财富","author":null,"published_at":"2026-07-13T10:24:25+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5jRjN3SjM0TkZYOFVsTENZUW40eHRCR0RubGJkNmhxV0hIWWh5VWxXTVpRcnN2WjZxbVRnci1qVGVNRmE4TTY4eUtGNFlWYzJLNWVzR2t4dy1iMWhiUzBKSQ?oc=5\" target=\"_blank\">宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">东方财富</font>","full_text":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在中国化妆品多肽原料行业，维琪科技以6.6%份额位列行业第一。\n客户方面，维琪科技已进入宝洁联合利华、资生堂等国际品牌商及科丝美诗集团、莹特丽集团、韩国科玛集团等国际化妆品制造商的供应商体系，并与丸美、凌博士、迪仕艾普、丝域养发、植物医生、樊文花、欧诗漫、野兽代码、溪木源、HBN、珀莱雅宝洁供应咖啡酰六肽-9原料产品，根据弗若斯特沙利文的研究报告，公司是国内首家向知名国际品牌销售创新新原料的化妆品原料供应商。\n值得注意的是，维琪科技提醒投资者，公司存在毛利率下滑的风险。若未来出现原材料价格及劳动力成本持续上涨、市场竞争加剧、ODM成品业务比例上升、下游客户需求减少等情形，而公司未能采取有效手段控制成本或产品议价能力下降，公司将面临产品成本上升或销售价格下降，高毛利率无法继续维持，进而导致经营业绩下滑的风险。\n（文章来源：21世纪经济报道）","excerpt":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在…","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 593 characters.","diagnostics_url":"/api/diagnose?url=https%3A//wap.eastmoney.com/a/202607133802724621.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 593 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":593,"summary_length":221,"usable_text_length":593,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":593,"summary_length":221}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道 - 东方财富","url":"https://wap.eastmoney.com/a/202607133802724621.html","summary":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在…","source":"东方财富","date":"2026-07-13T10:24:25+00:00","content":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在中国化妆品多肽原料行业，维琪科技以6.6%份额位列行业第一。\n客户方面，维琪科技已进入宝洁联合利华、资生堂等国际品牌商及科丝美诗集团、莹特丽集团、韩国科玛集团等国际化妆品制造商的供应商体系，并与丸美、凌博士、迪仕艾普、丝域养发、植物医生、樊文花、欧诗漫、野兽代码、溪木源、HBN、珀莱雅宝洁供应咖啡酰六肽-9原料产品，根据弗若斯特沙利文的研究报告，公司是国内首家向知名国际品牌销售创新新原料的化妆品原料供应商。\n值得注意的是，维琪科技提醒投资者，公司存在毛利率下滑的风险。若未来出现原材料价格及劳动力成本持续上涨、市场竞争加剧、ODM成品业务比例上升、下游客户需求减少等情形，而公司未能采取有效手段控制成本或产品议价能力下降，公司将面临产品成本上升或销售价格下降，高毛利率无法继续维持，进而导致经营业绩下滑的风险。\n（文章来源：21世纪经济报道）","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//wap.eastmoney.com/a/202607133802724621.html","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 593 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 593 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":593,"summary_length":221,"usable_text_length":593,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":593,"summary_length":221}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/35696","export_markdown":"/api/items/35696/export?format=markdown","export_json":"/api/items/35696/export?format=json","diagnose":"/api/diagnose?url=https%3A//wap.eastmoney.com/a/202607133802724621.html"},"formats":{"full":{"id":35696,"title":"宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道 - 东方财富","url":"https://wap.eastmoney.com/a/202607133802724621.html","source":"东方财富","author":null,"published_at":"2026-07-13T10:24:25+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在…","full_text":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在中国化妆品多肽原料行业，维琪科技以6.6%份额位列行业第一。\n客户方面，维琪科技已进入宝洁联合利华、资生堂等国际品牌商及科丝美诗集团、莹特丽集团、韩国科玛集团等国际化妆品制造商的供应商体系，并与丸美、凌博士、迪仕艾普、丝域养发、植物医生、樊文花、欧诗漫、野兽代码、溪木源、HBN、珀莱雅宝洁供应咖啡酰六肽-9原料产品，根据弗若斯特沙利文的研究报告，公司是国内首家向知名国际品牌销售创新新原料的化妆品原料供应商。\n值得注意的是，维琪科技提醒投资者，公司存在毛利率下滑的风险。若未来出现原材料价格及劳动力成本持续上涨、市场竞争加剧、ODM成品业务比例上升、下游客户需求减少等情形，而公司未能采取有效手段控制成本或产品议价能力下降，公司将面临产品成本上升或销售价格下降，高毛利率无法继续维持，进而导致经营业绩下滑的风险。\n（文章来源：21世纪经济报道）","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 593 characters.","diagnostics_url":"/api/diagnose?url=https%3A//wap.eastmoney.com/a/202607133802724621.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 593 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":593,"summary_length":221,"usable_text_length":593,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":593,"summary_length":221}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 593 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":593,"summary_length":221,"usable_text_length":593,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":593,"summary_length":221}},"actions":{"read":"/item/35696","export_markdown":"/api/items/35696/export?format=markdown","export_json":"/api/items/35696/export?format=json","diagnose":"/api/diagnose?url=https%3A//wap.eastmoney.com/a/202607133802724621.html"}},"digest":{"id":35696,"title":"宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道 - 东方财富","url":"https://wap.eastmoney.com/a/202607133802724621.html","source":"东方财富","topic":"peptides","published_at":"2026-07-13T10:24:25+00:00","excerpt":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新 行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 593 characters.","reading_time_min":1,"cluster_id":1656347},"card":{"display_title":"宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道 - 东方财富","subtitle":"东方财富 · 2026-07-13","summary":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新…","badges":["quality:high"],"links":{"read":"/item/35696","original":"https://wap.eastmoney.com/a/202607133802724621.html","diagnose":"/api/diagnose?url=https%3A//wap.eastmoney.com/a/202607133802724621.html"},"quality_warning":null},"export":{"title":"宝洁、联合利华供应商，“多肽原料第一股”今日申购丨打新早知道 - 东方财富","url":"https://wap.eastmoney.com/a/202607133802724621.html","summary":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在…","source":"东方财富","date":"2026-07-13T10:24:25+00:00","content":"7月13日，可申购一只新股，为北交所的维琪科技化妆品化妆品成品的研发、生产、销售以及相关服务，是专精特新\n行业地位方面，截至7月10日，维琪科技拥有22个获国家药监局批准备案的新原料，其中9个为创新新原料，公司新原料备案获批数量位居前列，创新新原料备案获批数量位居第一，处于行业领先地位。目前，少部分国内公司的开发水平已能从仿制肽阶段达到创新肽阶段，但这些公司推出产品的时间晚于维琪科技，数量亦少于维琪科技。根据弗若斯特沙利文的研究报告，在中国化妆品多肽原料行业，维琪科技以6.6%份额位列行业第一。\n客户方面，维琪科技已进入宝洁联合利华、资生堂等国际品牌商及科丝美诗集团、莹特丽集团、韩国科玛集团等国际化妆品制造商的供应商体系，并与丸美、凌博士、迪仕艾普、丝域养发、植物医生、樊文花、欧诗漫、野兽代码、溪木源、HBN、珀莱雅宝洁供应咖啡酰六肽-9原料产品，根据弗若斯特沙利文的研究报告，公司是国内首家向知名国际品牌销售创新新原料的化妆品原料供应商。\n值得注意的是，维琪科技提醒投资者，公司存在毛利率下滑的风险。若未来出现原材料价格及劳动力成本持续上涨、市场竞争加剧、ODM成品业务比例上升、下游客户需求减少等情形，而公司未能采取有效手段控制成本或产品议价能力下降，公司将面临产品成本上升或销售价格下降，高毛利率无法继续维持，进而导致经营业绩下滑的风险。\n（文章来源：21世纪经济报道）","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//wap.eastmoney.com/a/202607133802724621.html","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 593 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 593 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":593,"summary_length":221,"usable_text_length":593,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":593,"summary_length":221}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}